32 Biosciences, a leader in the field of gut microbiome medicine, today announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key regulatory milestones.

32 Biosciences is redefining the field of microbiome medicine through precision diagnostics and therapeutics. The company's mission is to revolutionize healthcare by defining, diagnosing, and restoring the functional health of the gut microbiome to prevent and treat chronic diseases, thereby improving health span and longevity.